Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know

Alexion Pharmaceuticals (ALXN) closed at $86.14 in the latest trading session, marking a +1.98% move from the prior day.

Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $82.50, moving +0.17% from the previous trading session.

Alexion (ALXN) Down 6.3% Since Last Earnings Report: Can It Rebound?

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Top Ranked Growth Stocks to Buy for February 4th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 4th

Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales

Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.

Top Ranked Growth Stocks to Buy for January 31st

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 31st.

Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.

Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Top Estimates

Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Why Earnings Season Could Be Great for Alexion (ALXN)

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Top Ranked Growth Stocks to Buy for January 29th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 29th.

Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study

Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.

Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.

The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management

The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management

Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.

Will Lower Revenues Dampen Corning's (GLW) Q4 Earnings?

Corning's (GLW) fourth-quarter performance is likely to have been hurt by changing market conditions that translated into lower sales at Optical Communications and Display Technologies segments.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.

Sejuti Banerjea headshot

Tesla's (TSLA) Unintended Acceleration Problem

A fresh lawsuit for unintended acceleration increase chances of a broader product recall.

Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma

Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.